tbuckley/cabot-search huggingface dataset:
AB0879 Fibromyalgia in patients with ankylosing spondylitis: prevalence and relationship with disease activity
Authors: M. Sahli, O. Saidane, I. Mahmoud, A. Ben Tekaya, R. Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Spondyloarthritis (SpA) is an inflammatory rheumatic disease, characterised by spinal involvement, peripheral arthritis, or enthesitis with marked pain, stiffness, and fatigue. Fibromyalgia (FM) may be associated with SpA, and shares some common symptoms. <h3>Objectives</h3> We aimed to estimate the prevalence of FM in SpA and its influence on the assessment of SpA disease activity. <h3>Methods</h3> This single-centre cross-sectional study included consecutive patients with SpA according to the Assessment of SpondyloArthritis International Society criteria. FM was diagnosed according to the 2010 American College of Rheumatology criteria. All patients underwent clinical evaluation of disease activity using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) and then compared in patients with and without FM. <h3>Results</h3> The study included 100 patients with SpA, 67 males and 33 females with a median age of 44.65 years. The prevalence of fibromyalgia was 20%. Patients fulfilling the criteria of FM presented a higher total BASDAI (5.86 (±1.97) vs. 3.15 (±1.99), p&lt;0.01), higher ASDAS-CRP (3.43 (±1.13) vs. 2.41 (±1), p&lt;0.01), higher ASDAS-VS (3.5 (±1.12) vs. 2.53 (±1.02), p&lt;0.01) and poorer function scores (BASFI) (6.76 (±1.97) vs. 3.8 (±2.59), p&lt;0.01). <h3>Conclusions</h3> FM is a frequent comorbidity in patients with SpA. In patients with SpA-FM, disease activity may be overestimated and this overestimation could lead to inappropriate treatment escalation. <h3>References</h3> [1] Azevedo VF, Paiva E dos S, Felippe LRH, Moreira RA. Occurrence offibromyalgia in patients with ankylosing spondylitis. Rev Bras Reumatol.2010;50:646–50. [2] Salaffi F, De Angelis R, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F.Fibromyalgia in patients with axial spondyloarthritis: epidemiological profileand effect on measures of disease activity. Rheumatol Int. 2014;34:1103–10. <h3>Disclosure of Interest</h3> None declared
Identification of Low‐Abundance Urinary Biomarkers in Lupus Nephritis Using Electrochemiluminescence Immunoassays
Authors: Samantha Stanley, Chi Chiu Mok, Kamala Vanarsa, Deena Habazi, Jennifer Li, Claudia Pedroza, Ramesh Saxena, Chandra Mohan
Journal: Arthritis & Rheumatology (2019)

Objective To investigate the utility of a sensitive platform using electrochemiluminescence ( ECL ) for the identification of low‐abundance urinary protein biomarkers in lupus nephritis ( LN ). Methods Forty‐eight urine samples were obtained from subjects in 2 independent cohorts, each consisting of 3 groups (matched for age, sex, and race) of 8 patients with active LN (renal Systemic Lupus Erythematosus Disease Activity Index [ SLEDAI ] &gt;0), 8 patients with inactive SLE (renal SLEDAI 0), and 8 healthy controls. Samples were tested using a preexisting 40‐plex ECL panel. A custom 5‐plex ECL panel was then developed for further validation studies and used to test 140 urine samples (from 44 patients with active LN, 41 patients with inactive SLE, 28 healthy controls, and 27 patients with other kidney diseases). Results Levels of 17 urinary proteins were elevated ( P &lt; 0.05 by 2‐tailed Mann‐Whitney U test) in samples from patients with active LN compared to samples from patients with inactive SLE and healthy controls in cohort 1, while 9 were similarly elevated in cohort 2. Of these, interleukin‐7 ( IL ‐7), IL ‐12p40, IL ‐15, interferon‐γ–inducible protein 10 ( IP ‐10), and thymus and activation–regulated chemokine ( TARC ) were chosen for further validation. These 5 proteins were undetectable by enzyme‐linked immunosorbent assay ( ELISA ). Hence, a custom 5‐plex ECL panel was developed and used to validate the results from the initial 40‐plex screening panel. Urinary IL ‐7, IL ‐12p40, IL ‐15, IP ‐10, and TARC levels were again significantly elevated in patients with active LN compared to those with inactive SLE and healthy controls, and correlated well with the renal SLEDAI and physician's global assessment of disease activity (R &gt; 0.67, P &lt; 0.05). All 5 urinary proteins were more frequently elevated in LN compared to controls with other chronic kidney diseases, although overall group differences attained significance only for urinary IL ‐7 and IL ‐15. Conclusion Urinary levels of IL ‐7, IL ‐12p40, IL ‐15, IP ‐10, and TARC are potentially useful diagnostic tools in LN . The use of ECL assays may allow detection of urinary biomarkers that are below ELISA detection limits.
Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling
Authors: Marilena Ciciarello, Giulia Corradi, Giorgia Simonetti, Giovanni Marconi, Sabina Sangaletti, Mario Paolo Colombo, Giovanni Martinelli, Michele Cavo, Antonio Curti
Journal: Blood (2018)
FRI0605 The development process of mobile health applications for self-management in patients with rheumatic and musculoskeletal diseases is heterogeneous and often incomplete: results of a systematic literature review
Authors: A. Najm, E. Nikiphorou, L. Gossec, F. Berenbaum
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Mobile health (mHealth) is exponentially growing in the current era, providing new potential and transforming the face of healthcare delivery. While the increasing availability of applications (apps) may enable people with rheumatic and musculoskeletal diseases (RMDs) to better self-manage their health, there is a general lack of evidence on ways to ensure appropriate development and evaluation of apps. <h3>Objectives</h3> To obtain an overview of existing mHealth apps for self-management in patients with RMDs, regarding content and development methods in particular, through a systematic literature review. <h3>Methods</h3> A search was performed up to December 2017 using EMBASE, Pubmed, Cochrane library, Web of Science and Psychinfo databases, with relevant key words and MeSH terms addressing three key domains: RMDs, self-management and mHealth. Double screening was performed on 15% of all abstracts against agreed inclusion criteria. For each publication relevant to an app for RMDs, the content, the aims, the target population of the apps and their development strategies were noted. The analysis was descriptive. <h3>Results</h3> Of 562 abstracts, 57 full text were screened. 39 articles were included in the analysis. 13 articles referred to an app linked to a connected device. Most of the apps targeted rheumatoid arthritis patients (n=11), juvenile idiopathic arthritis (n=7) and osteoarthritis (n=8). The development process of the app was poorly described in 19/39 (48.7%) of the studies (figure 1). Only 6/39 (15.4%) included patients, and 14/39 (35.9%) included health professionals or physicians in the development of such apps. Moreover, a qualitative phase occurred in only 6/39 (15.4%) of the cases. The app was tested and evaluated by physicians in 6/39 (15.4%). Patients were more frequently involved in app evaluation (29/39, 74.4%) but mostly indirectly through their adherence to the app. Only few of the apps published on were commercially available (5/39, 12.8%), 4/5 are free. One app is currently under development. <h3>Conclusions</h3> The development process of most apps was poorly described and potentially not satisfying in many studies. Despite patient willingness to use mHealth apps for self-management of their RMDs, a strong effort needs to be made to provide a standard and ensure quality and safety of newly-developed apps. This work will further inform EULAR points to consider for development, evaluation and implementation of mobile health applications for self-management of RMDs by patients. <h3>Disclosure of Interest</h3> None declared
Measles outbreak: preliminary report on a case series of the first 8,070 suspected cases, Manaus, Amazonas state, Brazil, February to November 2018
Authors: Guilherme Almeida Elidio, Giovanny Vinícius Araújo de França, Flávia Caselli Pacheco, Marinélia Martins Ferreira, Jair dos Santos Pinheiro, Eliane Nogueira Campos, Bernardino Cláudio de Albuquerque, Rosemary Costa Pinto, Angela Desiree Carepa Santos da Silva, Priscila Leal e Leite, Greice Madeleine Ikeda do Carmo, Andre Luiz de Abreu, Cintia Paula Vieira Carrero, Marli Rocha de Abreu, Fabiano Marques Rosa, Cesar M. de Oliveira, Dirce Bellezi Guilhem
Journal: Eurosurveillance (2019)

We report an ongoing measles outbreak in Manaus, Amazonas state, Brazil. As at 3 November 2018, 1,631 cases were confirmed corresponding to an incidence of 75.3 per 100,000 inhabitants; all five sanitary districts presented confirmed cases. Reintroduction of measles virus in Manaus is likely related to the current outbreak in Venezuela and due to recent decline in measles vaccine coverage. Given the current scenario, prevention and control measures should target individuals aged 15-29 years.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
Authors: R.S. Herbst, P. Baas, J.L. Perez-Gracia, E. Felip, D.-W. Kim, J.-Y. Han, J.R. Molina, J.-H. Kim, C. Dubos Arvis, M.-J. Ahn, M. Majem, M.J. Fidler, V. Surmont, G. de Castro, M. Garrido, Y. Shentu, K. Emancipator, A. Samkari, E.H. Jensen, G.M. Lubiniecki, E.B. Garon
Journal: Annals of Oncology (2019)

BackgroundIn KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes in patients based on PD-L1 expression in archival versus newly collected tumor samples using recently updated survival data.Patients and methodsPD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) in archival or newly collected tumor samples. Patients received pembrolizumab 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W for 24 months or until progression/intolerable toxicity/other reason. Response was assessed by RECIST v1.1 every 9 weeks, survival every 2 months. Primary end points were OS and progression-free survival (PFS) in tumor proportion score (TPS) ≥50% and ≥1%; pembrolizumab doses were pooled in this analysis.ResultsAt date cut-off of 24 March 2017, median follow-up was 31 months (range 23–41) representing 18 additional months of follow-up from the primary analysis. Pembrolizumab versus docetaxel continued to improve OS in patients with previously treated, PD-L1-expressing advanced NSCLC; hazard ratio (HR) was 0.66 [95% confidence interval (CI): 0.57, 0.77]. Of 1033 patients analyzed, 455(44%) were enrolled based on archival samples and 578 (56%) on newly collected tumor samples. Approximately 40% of archival samples and 45% of newly collected tumor samples were PD-L1 TPS ≥50%. For TPS ≥50%, the OS HRs were 0.64 (95% CI: 0.45, 0.91) and 0.40 (95% CI: 0.28, 0.56) for archival and newly collected samples, respectively. In patients with TPS ≥1%, OS HRs were 0.74 (95% CI: 0.59, 0.93) and 0.59 (95% CI: 0.48, 0.73) for archival and newly collected samples, respectively. In TPS ≥50%, PFS HRs were similar across archival [0.63 (95% CI: 0.45, 0.89)] and newly collected samples [0.53 (95% CI: 0.38, 0.72)]. In patients with TPS ≥1%, PFS HRs were similar across archival [0.82 (95% CI: 0.66, 1.02)] and newly collected samples [0.83 (95% CI: 0.68, 1.02)].ConclusionPembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of patients with newly collected and archival samples.Trial registrationClinicalTrials.gov: NCT01905657.
AB0876 Correlation between faecal calprotectin levels and tobacco use in patients with spondyloarthritis and without previous diagnosis of inflammatory bowel disease
Authors: M. Espinosa Malpartida, C. Ramos Giráldez, C. Merino Argumánez, M.B. Ruiz-Antorán, J. Campos Esteban, C. Barbadillo Mateos, H. Godoy Tundidor, B. Agudo Castillo, Y. González Lama, J.L. Andreu Sánchez, J. Sanz Sanz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> It is estimated that between 5% and 10% of patients with spondyloarthritis (SpA) are associated with inflammatory bowel disease (IBD). It has also been proven through endoscopic and histological studies that up to 60% of patients with SpA have microscopic inflammatory intestinal lesions, with a subclinical character and of which the true clinical relevance is unknown, although a greater percentage of these are those that will evolve to IBD. <h3>Objectives</h3> To assess whether tobacco use may be associated with higher faecal calprotectin (FC) levels in patients with diagnosis of SpA and without clinical suspicion or previous diagnosis of IBD. <h3>Methods</h3> TThis is a single centre, cross-sectional, observational study with prospective collecting data. Data were included for consecutive patients from Rheumatology consultation who had been previously diagnosed of SpA, fulfilled ASAS criteria and without digestive symptoms suggestive of IBD (chronic diarrhoea, rectal bleeding, perianal disease, chronic abdominal pain – persistent or recurrent). Details about demographic characteristics, clinical and laboratory variables related with SpA (BASDAI, HLA B27, acute phase reactants), treatments and FC were collected. A pathological cut-off point of FC&gt;50 mg/kg was determined. Patients on NSAIDs treatment were advised to discontinue its use 2 weeks before collecting stool samples. This study was approved by the Clinical Research Ethics Committee. <h3>Results</h3> 99 patients were included: 53.5% women, with a mean age of 46±11 years. nonspecific digestive disorders (dyspeptic symptoms, H. pylori y gastroesophageal reflux) were observed in 9% of the patients. Among all, 18% were smokers. Mean BASDAI was 3.7±2.5; 39% of patients were being treated with any concomitant DMARD and 67% were on NSAIDs. 49.5% of the patients<sup>49</sup> showed elevated FC determinations, with an mean level of 276 mg/kg (range 52–3,038). The percentage of patients with high levels of FC was significantly increased in smokers (72.2% vs. 44.4%, p. 0.033), with higher levels of FC in smokers than non-smokers (262 mg/L vs. 121 mg/L. p. 0.126). The remaining analysed variables did not show any significant differences in terms of FC levels. <h3>Conclusions</h3> Microscopic bowel inflammation is described in approximately 50% of patients with SpA and it is related with more severe disease. Tobacco use has been associated with worse prognosis and response to treatment in SpA. A relationship between elevated FC levels (inflammatory activity biomarker) and tobacco use in patients with SpA without previous diagnosis or clinical suspicion of IBD is established in this study. <h3>Disclosure of Interest</h3> None declared
The Weight of the White Coat
Authors: Anna Goshua
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0739-HPR Expert recommendations on psychological needs of patients with rheumatoid arthritis
Authors: L. León, M. Redondo, A. Fernández-Nebro, S. Gómez, E. Loza, M. Montoro, R. García-Vicuña, M. Galindo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives:</h3> To generate recommendations in order to: 1) Optimize the management of psychological needs of RA patients, their family and caregivers; 2) Promote and improve communication and decision making with patients; 3) Establish referral criteria to mental health professionals. <h3>Methods:</h3> A nominal group meeting of RA experts, rheumatologists and psychologists was held, in which the most important psychological and emotional needs and related aspects in RA were addressed. With an extensive review of the literature, a set of preliminary recommendations was generated that the experts discussed and modified. The definitive recommendations were voted in a Delphi which was extended to 20 more professionals. Participants voted from 1 (strongly disagree) to 10 (totally agree). Agreement was considered if at least 70% voted ≥7 (GA). Each recommendation was assigned a level of evidence (LE) and a grade of recommendation (GR) according to the Center for Evidence Based Medicine of Oxford. <h3>Results:</h3> A total of 13 recommendations were generated (see table 1). <h3>Conclusions:</h3> These recommendations will help health professionals address psychological needs of the patient in daily practice, in order to manage them and improve patient's quality of life. <h3>Disclosure of Interest:</h3> None declared
THU0049 Development of tfh-th1 like cells through epigenetic modification by stats family factors in patients with systemic lupus erythematosus
Authors: X. Ma, S. Nakayamada, S. Kubo, K. Sakata, K. Yamagata, Y. Tanaka
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a prototype of autoimmune disease characterised by chronic immune activation and multiple immunologic phenotypes<sup>(1)</sup>. Among several types of immune cells, T follicular helper (Tfh) cells serve important roles in the development and progression of SLE<sup>(2)</sup>. <h3>Objectives</h3> To assess the characteristics and mechanisms of differentiation of Tfh cells, we probed the phenotype of T helper cells in patients with SLE and underlying epigenetic modifications by cytokine-induced signal transducer and activators of transcription (STAT) family factors. <h3>Methods</h3> Naive CD4<sup>+</sup> T cells and memory CD4<sup>+</sup> T cells were isolated and stimulated by various cytokines and T cell receptor (TCR) <i>in vitro</i>. Expression of characteristic markers of Tfh-Th1-cells and phosphorylation of STATs were analysed by flow cytometry and qPCR. Histone modifications were evaluated by chromatin immunoprecipitation. Peripheral blood mononuclear cells from SLE patients and healthy controls were analysed by flow cytometry and productions of cytokines in serum were tested by cytometric bead array. <h3>Results</h3> Differentiation of CXCR5<sup>+</sup>CXCR3<sup>+</sup>Bcl-6<sup>+</sup>T-bet<sup>+</sup>IL-21<sup>+</sup>IFN-γ<sup>+</sup> Tfh-Th1-like cells was induced by IL-12. Among STAT family, STAT1 and STAT4 were phosphorylated simultaneously by IL-12 independent of IFN-γ and directly bound on Bcl-6 and T-bet gene loci accompanied by suppression of trimethylated histone 3 lysine 27. Compared with healthy controls, responsiveness of activation of STAT1 and STAT4 by IL-12 and proportion of activated Tfh-Th1-like cells were increased in patients with SLE. <h3>Conclusions</h3> Our findings suggest that IL-12-mediated co-activation of STAT1 and STAT4 alter histone modification, resulting in development of Tfh-Th1-like cells that are characteristically expanded in patients with SLE. These findings could be one of underlying pathogenesis of SLE and potentially helpful towards development of cell-specific treatment. <h3>References</h3> [1] Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–21. [2] Suarez-Fueyo A, et al. T cells in systemic lupus erythematosus. Curr Opin Immunol2016;43:32–8. <h3>Acknowledgements</h3> The authors thank Ms. N. Sakaguchi for the excellent technical assistance. <h3>Disclosure of Interest</h3> None declared
FRI0364 Clinical and diagnostic significance of immunoglobulin a rheumatoid factor in primary sjogren’s syndrome
Authors: H.-R. Kim, K.-A. Lee, S.-H. Lee
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid factors (RFs) are among the autoantibodies associated with Primary Sjogren's syndrome (pSS). Although measurement of non-IgM RFs is not performed routinely in clinical practice due to technical difficulties, RFs can belong to any isotype. A few studies have suggested the prognostic value of non-IgM RFs in pSS. However, few studies evaluated the clinial and diagnostic value of non-IgM RF in pSS. <h3>Objectives</h3> This present study aimed to answer the question on whether the RF isotype has a potential diagnostic value for the detection of pSS, particularly for distinguishing pSS from idiopathic sicca syndrome. In addition, we assessed whether IgA RF may serve as a prognostic factor by evaluating their association with clinical and serological characteristics. <h3>Methods</h3> RF levels were measured in 85 and 38 patients with pSS and idiopathic sicca syndrome, respectively, using the ELISA and analysed with respect to clinical and laboratory disease characteristics. ROC curves were used to determine and compare the diagnostic accuracy of IgA RF with other diagnostic tests. <h3>Results</h3> Serum levels of IgA RF were significantly higher in patients with pSS than in those with idiopathic sicca syndrome. IgA RF showed a sensitivity, specificity, positive, and negative predictive value of 90.7%, 78.9%, 89.5%, and 81.1%, respectively, for pSS diagnosis. IgA RF was associated with xerostomia; abnormal Schirmer's test; severe sialoscintigraphic grade; low unstimulated salivary flow rate (USFR); antinuclear antibody and anti Ro/SSA positivity; high IgG and IgM/G RF levels; and low C3 levels in patients with pSS. IgA RF titres had positive correlations with sialoscintigraphic grade and IgG and IgG/M RF levels and had negative correlations with USFR, Schirmer's test value, and C3 levels (figure 1). <h3>Conclusions</h3> Our findings confirmed the potential of IgA RF to distinguish pSS from idiopathic sicca syndrome. The presence of IgA RF in patients with pSS was associated with significantly worse exocrine function and active serologic profile. No association between IgA RF and extra-glandular manifestations was noted. <h3>References</h3> [1] Rischmueller M, Tieu J, Lester S. Primary Sjogren's syndrome. Best practice &amp; research Clinical rheumatology2016;30(1):189–220. [2] Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Disease markers2013;35(6):727–34. <h3>Acknowledgements</h3> This work was funded by the Konkuk University Medical Centre Research Grant 2016. <h3>Disclosure of Interest</h3> None declared